The tumor microenvironment is profoundly immunosuppressive. We show that multiple tumor types create intratumoral immune suppression driven by a specialized form of regulatory T cell (T reg ) activation dependent on the PTEN (phosphatase and tensin homolog) lipid phosphatase. PTEN acted to stabilize T regs in tumors, preventing them from reprogramming into inflammatory effector cells. In mice with a T reg -specific deletion of PTEN, tumors grew slowly, were inflamed, and could not create an immunosuppressive tumor microenvironment. In normal mice, exposure to apoptotic tumor cells rapidly elicited PTEN-expressing T regs , and PTEN-deficient mice were unable to maintain tolerance to apoptotic cells. In wild-type mice with large established tumors, pharmacologic inhibition of PTEN after chemotherapy or immunotherapy profoundly reconfigured the tumor microenvironment, changing it from a suppressive to an inflammatory milieu, and tumors underwent rapid regression. Thus, the immunosuppressive milieu in tumors must be actively maintained, and tumors become susceptible to immune attack if the PTEN pathway in T regs is disrupted.
INTRODUCTION
Tumors are not invisible to the immune system (1) (2) (3) (4) . Analysis of patients' T cells suggests that many patients are chronically attempting to mount an immune response against their own tumors (5-8). However, in almost all cases, this attempted response is suppressed by potent inhibitory mechanisms within the tumor microenvironment. Multiple mechanisms contribute to this suppression (9) , but one key component is the Foxp3 + regulatory T cell (T reg ) system. Tumors actively recruit T regs , and the T regs in tumors become highly activated (10) . If T regs are transiently ablated in tumor-bearing mice, then the immune system rapidly attempts to attack the tumor (11, 12) . However, in these models, complete depletion of T regs leads to lethal autoimmunity, yet partial depletion of T regs is not sufficient to reverse the suppressive milieu in the tumor (13) . To date, it has not been possible to preferentially target the T regs that are protecting the tumor.
To improve this selectivity, we asked whether tumors might preferentially depend on certain molecular pathways to activate T regs . This activation step is a critical control point in T reg biology, because even fully mature T regs require specific activation signals to become functionally suppressive (14) . These signals include engagement of the T cell antigen receptor (TCR) (15, 16) . However, antigen specificity alone does not confer selectivity for tumors, because many of the T regs in tumors appear to recognize normal self-antigens (17) . Besides antigen, T regs also integrate a variety of modulating signals from the local microenvironment during activation (18) . This can produce "tailored" forms of activation, with distinct patterns of transcription factors and functional activity (19) . We hypothesized that the unique environment of tumors might preferentially elicit certain characteristic pathways of T reg activation.
The lipid phosphatase PTEN (phosphatase and tensin homolog) has recently been identified as an important signaling pathway in T regs (20, 21) . Targeted deletion of PTEN causes T reg instability (20) , leading to progressive conversion into proinflammatory effector cells (so-called ex-T regs ), and eventual lupus-like autoimmunity. However, the mechanism by which PTEN stabilizes T regs and the role that this might play in tumor biology remain unknown. Here, we show that many T regs in the tumor microenvironment constitutively express PTEN and rely on this pathway to maintain their suppressive function. PTEN signaling in T regs is required for the immune system to suppress responses to apoptotic cells, including apoptotic tumor cells. If this PTEN pathway is interrupted, then tumors lose the ability to create their usual highly suppressive milieu. The T regs in tumors are destabilized and reprogram into inflammatory effector cells, the tumor milieu becomes proinflammatory and immunogenic, and even large established tumors undergo rapid regression. which can be up-regulated in tumors by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO), as we have shown (22) . IDO promotes tolerance and immunosuppression in the immune system (23) , and it can directly activate T regs in tumors (22, 24) . These same PD-1 + Eos HI T regs also coexpressed PTEN phosphatase (Fig. 1A , right-hand panels).
To help elucidate the connection between IDO, PD-1, and PTEN in activated T regs , we used the in vitro culture system shown in fig. S2 . Resting T regs were activated by coculture with IDO-expressing dendritic cells (DCs) and activated effector cells. After initial activation by IDO, the T regs then became strictly dependent on PD-1 to maintain their functional activity ( fig. S2A ). We hypothesized that the IDO and PD-1 pathways might converge at the level of Akt kinase. In most T cells, high Akt signaling is required for normal activation; however, T regs are unusual in that they must keep Akt signaling low during activation or else they will lose their suppressive phenotype (25) . PD-1 is known to inhibit Akt via the activation of PTEN phosphatase (26, 27) , but the effect of IDO on Akt was unknown. We found that IDO inhibited phosphorylation of Akt on Ser 473 ( fig. S2B ). Ser 473 is the target of the mTOR TORC2 complex; consistent with this, pharmacologic inhibition of mTOR could fully substitute for IDO during T reg activation ( fig. S2C ). In vivo, administration of an IDO inhibitor drug to tumor-bearing mice increased pAkt 473 phosphorylation in T regs ( fig. S3 ). Thus, both IDO and PD-1 appeared to restrain excessive Akt signaling in activated T regs .
The phosphorylation status of Akt is only a proxy marker and is very labile. We sought a more stable biomarker that might reflect the longer-term impact of dysregulated Akt signaling on the overall T reg phenotype. The transcription factor FoxO3a is important in T reg function (28) , and it is sensitive to the activity of Akt (29) (30) (31) . In the short term, phosphorylation by Akt drives nuclear exclusion of FoxO3a and blocks its function (32) , but in the long term, overactivity of Akt leads to degradation of FoxO3a (33) . Fluorescence-activated cell sorting (FACS) analysis of T regs showed that FoxO3a expression was highly bimodal, with some T regs expressing none and some having strongly positive expression ( fig. S4 ). In vitro, after activation cocultures, the fraction of T regs that became FoxO3a-positive tracked with the suppressor activity controlled by IDO and mTOR ( fig. S5A ), whereas on a cell-by-cell basis, those T regs that expressed PD-1 also coexpressed FoxO3a (Fig. 5B) . Functionally, T regs from FoxO3-deficient mice (28) were selectively unable to mediate the form of suppressor activity created by the IDO and PD-1, even though conventional CD3-induced T reg activity remained intact ( fig. S5C ). Thus, although FoxO3a itself was not unique or restricted only to IDO and PD-1 (29, 30), we hypothesized that loss (down-regulation) of FoxO3a could be an informative biomarker for loss of the suppressive T reg phenotype of interest.
IDO and PD-1 acted sequentially. IDO up-regulated expression of PD-1 on the T regs via a process requiring tryptophan depletion and signaling via the amino acid-sensitive GCN2 kinase (34) (figs. S6 and S7, A to C). PD-1 was then required to maintain the IDO-induced activation state ( fig. S8) . If the PD-1 pathway was blocked, then Akt phosphorylation rapidly became high, FoxO3a was lost, and suppression activity was abrogated. On the basis of these findings, we hypothesized the model shown in Fig. 1B , in which IDO and PD-1 sequentially act to maintain the suppressive T reg phenotype. The key implication of this model was that maintenance of the suppressive phenotype required continuous, ongoing control of Akt: If this control was disrupted, then the suppressive phenotype was rapidly lost. Thus, the critical leverage point for continued suppression became PD-1 signaling via PTEN.
Maintenance of the T reg activation state by PTEN PTEN is an important target for multiple upstream pathways, because it inhibits phosphatidylinositol 3-kinase (PI3K) and thus limits phosphorylation of Akt (26, 27) . In addition to PD-1, PTEN is also downstream of neuropilin-1, a potent activator of T regs (29) . To assess the role of PTEN, we crossed mice bearing a floxed PTEN allele (35) with Bac-transgenic mice expressing a Cre-GFP (green fluorescent protein) fusion protein under the Foxp3 promoter (36) . This Cre strain deletes in~95% of Foxp3 + T regs (36) . Consistent with this, our PTEN Treg -KO mice expressed Cre-GFP in~95% of Foxp3 + cells and showed no detectable PTEN expression in Foxp3 + T regs from tumors or tumordraining lymph nodes (TDLNs) (fig. S9 ). The phenotype of this particular Cre/lox intercross was somewhat less penetrant than other PTENdeficient strains that have been described (20) , in that our mice were healthy when young and did not develop spontaneous autoimmunity until later in life (which is an important advantage for tumor studies). However, even in our young, healthy PTEN Treg -KO mice, the T regs were unable to control phosphorylation of Akt at Thr 308 during T reg activation in vitro (Fig. 1C ) and could not maintain the activated FoxO3a + PD-1 + suppressive phenotype after re-sorting ( Fig. 1 , D and E). This was not due to a global defect in all T reg activity, because conventional CD3-induced T reg activity remained intact in these mice (Fig. 1E) . Thus, the defect in PTEN Treg -KO T regs was a selective one, but-at least in the case of IDO-it profoundly compromised their ability to maintain the activated T reg phenotype.
We next asked whether PTEN could be pharmacologically targeted. PTEN inhibitor drugs are under active preclinical investigation for their neuroprotective and cardioprotective effects; we tested VO-OHpic, a high-affinity small-molecule inhibitor of PTEN (37) , for its ability to block suppression by IDO-activated T regs in vitro (Fig. 1F ). In the absence of any T regs , VO-OHpic had no effect on the readout T cells (neither toxic nor stimulatory). When control CD3-activated T regs were added, VO-OHpic had no effect on their ability to suppress. However, when the same T regs were activated by IDO, VO-OHpic fully blocked their suppressor activity, in a dose-dependent fashion. This was accompanied by progressive increase in phosphorylation of Akt in the T regs and progressive loss of detectable FoxO3a (Fig. 1G) Fig. 2A) . Slower growth was also seen with E.G7 (EL4-OVA) and LLC tumors ( fig. S10 ). Analysis of immune cells infiltrating the tumors (Fig. 2B) showed that wild-type hosts contained many PTEN + T regs that also coexpressed FoxO3a and PD-1, consistent with a suppressive phenotype. In contrast, the T regs in PTEN Treg -KO tumors did not express FoxO3a or PD-1; instead, they appeared unstable, with many expressing proinflammatory markers such as interleukin-2 (IL-2), CD40L, and IL-17 (Fig. 2B, lower panels, and fig. S11 ). All of these "reprogrammed" T regs continued to express residual Foxp3 (Fig. 2B , bottom graph), thus showing that they were derived from former T regs . The presence of these unstable, reprogrammed T regs is consistent with our previous descriptions of T reg reprogramming in tumors when IDO is blocked 22, 38) . Similar unstable ex-T regs have been described during autoimmunity in mice with targeted deletion of PTEN in T regs (20) .
The tumor-infiltrating CD8 + T cells in PTEN Treg -KO hosts appeared more activated (Fig. 2C) , which has been associated with antitumor immune surveillance (39) . Many of these CD103 + DCs produced IL-6 (bottom panels). This was significant because, as we will show, IL-6 proved to be a key driver of T reg reprogramming. Similar changes were seen when E.G7 lymphoma tumors were grown in PTEN Treg -KO hosts ( fig. S12 ).
These inflammatory changes were physically localized only to the tumor and TDLNs (Fig. 2E ). Elsewhere in these (young, healthy) PTEN Treg -KO hosts, the T cells and DCs appeared normal. This was informative, because it showed that the tumor became a potent local stimulus for inflammation when the host lacked the PTEN-T reg pathway.
In PTEN Treg -KO hosts, antigen-specific CD8 + T cells became aware of tumor-associated antigens after chemotherapy. Mice with established B16F10 tumors were treated with a single dose of CTX to release tumor antigens and then received a CFSE-labeled cohort of resting pmel-1 T cells, reactive with a tumor-associated gp100 antigen. In PTEN Treg -KO hosts, the resting pmel-1 cells became activated and proliferated in tumors, whereas proliferation was suppressed in wild-type hosts (Fig. 2F) . Similarly, when tumor-bearing mice were treated with T cell adoptive transfer and antitumor vaccination, PTEN Treg -KO hosts supported generalization of the immune response to new, additional T cells, recognizing antigen derived only from the tumor (Fig. 2G ). No such epitope spreading occurred in wild-type hosts. (In all of these studies, the readout T cells were purified by negative selection, because this was important to prevent artifactual activation, as shown in fig. S13 .) Thus, taken together, in PTEN Treg -KO hosts, tumors were unable to create their usual suppressive tumor microenvironment and instead were regarded by the immune system as spontaneously inflammatory and immunogenic.
Reconfiguration of the suppressive microenvironment in established tumors
We next asked whether a similar antitumor inflammatory response could be induced in wild-type mice by pharmacologic inhibition of PTEN. This was a more demanding setting because the tumor had already established a suppressive milieu. Administering PTEN inhibitor by itself had no effect on growth of established tumors; however, if mice also received immunotherapy (vaccine plus pmel-1 T cells), then blocking PTEN had a potent effect, allowing rapid regression of tumors (Fig. 3A) . Similar results were seen with ovalbumin (OVA)-expressing EL4 tumors and anti-OVA vaccine (Fig. 3B) .
Analysis of treated tumors revealed that phosphorylation of Akt in T regs remained low when tumors received only vaccine/T cells alone, but Akt phosphorylation became high when the PTEN inhibitor was added (Fig. 3C , red histograms). Phosphorylation was increased at both Thr 308 and Ser 473 sites. This is the expected pattern during activation of conventional (non-T reg ) CD4 + cells (40) , but it should not occur in T regs , which need to keep Akt activity low. Thus, blocking PTEN caused dysregulated control of Akt in T regs . (Notably, the T regs were analyzed after 4 days of treatment; thus, Akt phosphorylation reflected the whole process of activation and destabilization, over and above the direct effects of the PTEN inhibitor on Thr 308 .) Consistent with their inability to control Akt activity, intratumoral T regs in PTEN Treg -KO mice lost detectable FoxO3a and PD-1 ( Fig.  3C , dot plots). They also became destabilized and up-regulated proinflammatory IL-2 and CD40L (that is, underwent reprogramming). As a biologic control for these effects, we included the PI3K-d inhibitor CAL-101 (41), which inhibits T reg activity but does not affect PTEN. When tested in our in vitro model, CAL-101 inhibited T reg activation as expected, but it was not selective, inhibiting both IDO-induced and CD3-induced suppression ( fig. S14 ). In vivo, CAL-101 did not increase Akt phosphorylation in T regs , did not cause loss of FoxO3a and PD-1, and did not drive T reg destabilization and reprogramming (Fig. 3C ). In our previous studies of T reg reprogramming, we had shown that TCR-mediated activation is strictly required for reprogramming to occur (22, 38, 42) . Thus, CAL-101 appeared to inhibit all T reg activation (41), including the "destabilizing" activation that was required to drive reprogramming, whereas VO-OHpic allowed activation, but in a destabilizing fashion.
Further characterization of the tumor milieu after VO-OHpic treatment showed that vaccine-specific OT-I cells were suppressed when PTEN was active but were able to proliferate and up-regulate granzyme B when PTEN was blocked (Fig. 3D ). Tumors also contained more activated, proinflammatory Ly6c
+ myeloid DCs when PTEN was blocked, and the DCs expressed more CD86 and less PD-L1 (Fig. 3D , lower panels). The contribution of the immunotherapy regimen (T cells and vaccine) was important, because successful transformation of the tumor microenvironment required both vaccine-activated T cells and inhibition of PTEN (Fig. 3E) .
Finally, we noted that the PTEN inhibitor itself had no effect on a normal vaccine response in the absence of tumor (fig. S15A ). The same was true for genetic ablation of PTEN ( fig. S15B ): In the absence of a suppressive tumor, ablating PTEN had no effect on the response to vaccine. Thus, the effect of PTEN inhibition was to reverse the specific tumor-induced suppression, rather than to nonspecifically augment all immune responses. PTEN-T regs and tolerance to apoptotic cells PTEN + T regs were crucial for tumors, but it was not clear what role these cells normally played in the immune system. Other strains of mice with T reg -specific deletion of PTEN develop a spontaneous lupuslike autoimmunity as they age (20) . Such "lupus-prone" phenotypes can reflect an inability to maintain tolerance to apoptotic cells (43) . We have previously shown that apoptotic cells are potent inducers of IDO, and IDO-deficient mice fail to create tolerance to apoptotic cells and instead develop lupus autoimmunity (23) . We triggered apoptosis in EL4 tumor cells by in vitro treatment with staurosporine for 4 hours, and then injected the apoptotic tumor cells into normal, tumor-free mice. Apoptotic tumor cells drove extensive up-regulation of IDO in draining LNs (DLNs) (Fig. 4A ). This IDO expression was functionally important, because mice treated with an IDO inhibitor became responsive to antigen from the apoptotic cells, whereas responses were suppressed if IDO was active (Fig. 4B) . Apoptotic tumor cells elicited a prominent population of PTEN + T regs expressing FoxO3a + and PD-1 + in local DLNs, and induction of these T regs was blocked by the IDO inhibitor (Fig. 4C ). When T regs were sorted from DLNs after challenge with apoptotic cells, these T regs mediated potent, spontaneous suppression ex vivo, in the PD-1-dependent fashion characteristic of IDO-induced activation (Fig. 4D) . In contrast, T regs from resting LNs showed no spontaneous suppressor activity. [Readout assays in these experiments were driven by cognate antigen, with no CD3 mitogen, and under these conditions, resting T regs do not show spontaneous suppression (14 + myeloid DCs, and the readout OT-I T cells were able to respond to antigens from apoptotic cells (lower rows). Similar results were seen when genetically defined PTEN Treg -KO mice were challenged with apoptotic cells (Fig. 4E, right-hand plots) . In these PTEN Treg -KO mice, there was no additional effect of adding VO-OHpic, suggesting that the PTEN expressed in T regs was an important target of VO-OHpic in this model.
On the basis of the response to apoptotic tumor cells, we asked whether the PTEN Treg -KO mice had a generalized defect in tolerance to all apoptotic cells. Although the mice in our strain were healthy when young, some of the older mice (>1 year) spontaneously developed antinuclear antibody and immune complex deposition in the kidney, consistent with lupus-like autoimmunity (Fig. 4F) . Therefore, to test the younger, asymptomatic PTEN Treg -KO mice for an underlying defect in tolerance, we challenged them with intravenous injection of apoptotic thymocytes. These were syngeneic cells, and wild-type mice were fully tolerant to them; however, the PTEN Treg -KO mice showed widespread B cell activation (assessed as loss of CD24, Fig. 4G ) and rapidly developed multiple autoantibodies against classic apoptotic cell antigens (nucleosome, double-stranded DNA, and histone; Fig. 4H ). Thus, when confronted with large numbers of apoptotic cells, the PTEN pathway in T regs appeared critical for the host to create immune suppression and tolerance.
Synergy between chemotherapy and PTEN inhibition
Chemotherapy releases a wave of dying tumor cells. We hypothesized that the tumor might become critically dependent on the PTEN pathway after chemotherapy. Mice bearing established B16F10 tumors received a single injection of CTX, with or without VO-OHpic (Fig.  5A ). The dose of CTX was modest and by itself had no effect on these resistant tumors. VO-OHpic alone also had no effect on tumor growth. However, together these agents displayed striking synergy, causing rapid shrinkage of the tumor within 4 to 5 days. Mice received no other immunotherapy or T cell transfer; hence, any immunologic effects were the spontaneous contribution of the host immune system. Chemotherapy plus VO-OHpic was well tolerated, without weight loss or other obvious toxicity. In validation studies, mice without tumors were treated with VO-OHpic for up to 21 days and did not develop detectable autoantibodies (fig. S16) .
In this chemotherapy model, inhibiting PTEN caused much more potent synergy than inhibiting IDO, which causes growth delay but not tumor regression as we have previously shown (44) . However, combining an IDO inhibitor with VO-OHpic conferred additional benefit, delaying the regrowth of the tumor and prolonging the duration of response ( fig. S17A ). This was consistent with our in vitro model, in which PTEN maintained the function of T regs that were already activated, but IDO contributed to activation of new T regs . LLC lung carcinoma tumors also showed synergy between chemotherapy and inhibition of PTEN ( fig. S17B ).
Immune activation after chemotherapy when PTEN is inhibited When PTEN was inhibited, the response of the host immune system to chemotherapy became fundamentally changed. Phosphorylation of Akt in T regs went up (Fig. 5B) , with associated loss of FoxO3a expression (Fig. 5C ). T regs were destabilized, as shown by reprogramming (expression of IL-2 and CD40L, Fig. 5C, lower panels) . DCs acquired the activated myeloid DC phenotype (CD11b + CD103 + ) and many began to express IL-6, whereas PD-L1 was reduced and CD86 was markedly increased (Fig. 5D) . In contrast, the T regs and DCs from control mice receiving the PI3K-d inhibitor CAL-101 showed none of these changes (Fig. 5, B to D) . Functionally, both CAL-101 and VO-OHpic enhanced the antitumor effect of CTX, but VO-OHpic drove more sustained tumor regression ( fig. S18 ). We hypothesized that the response to VO-OHpic might be related to the beneficial inflammatory effects of the destabilized (reprogrammed) T regs . To test this, tumors were grown in mice with a transgenic diphtheria toxin receptor (DTR) under the control of the Foxp3 promoter, thus allowing global depletion of T regs by administration of diphtheria toxin (DT, fig.  S19 ). Ablation of T regs with DT modestly enhanced the effect of CTX, but this effect was much less than the effect of VO-OHpic, and tumors showed no regression. When mice received both VO-OHpic and T reg ablation, the superior efficacy of VO-OHpic was lost, and the response became equivalent to DT ablation alone. Thus, the destabilized T regs appeared to be an important driver of the antitumor response.
To directly test this, we bred mice that lacked the ability to undergo T reg reprogramming by ablating the IL-6 receptor on T regs (IL6R Treg -KO mice). We have previously shown that IL-6 is required to drive T reg reprogramming (22, 38) , which has also been seen by others (45, 46) . S20 , B and C). Thus, T reg reprogramming was functionally required for the synergy between VO-OHpic and chemotherapy, consistent with the role of PTEN in maintaining T reg stability (20, 21) .
We next tested the contribution of effector CD8 + T cells. Studies in Rag-deficient mice showed that adaptive immunity was strictly required (Fig. 5E ). To follow a known population of tumor-reactive CD8 + T cells during treatment, we pretransferred a cohort of Thy1.1 congenic pmel-1 T cells into normal wild-type host mice before implanting tumors (Fig. 5F ). In untreated mice, pmel-1 cells in the tumor appeared unactivated (no expression of CD69, 1B11, or IFN-g) and many expressed PD-1, suggestive of an exhausted phenotype. In contrast, when mice were treated with CTX + VO-OHpic, the pmel-1 cells in tumors down-regulated PD-1, and many now expressed CD69, 1B11, and IFN-g. Finally, we used antibody-mediated depletion to determine whether endogenous CD8 + T cells were required. Depletion of CD8 + cells completely abrogated the antitumor effect of CTX + VO-OHpic (Fig. 5G) , and the intratumoral T regs did not lose their FoxO3a + PD-1 + (suppressive) phenotype. This was consistent with our previous reports (22) showing that T reg destabilization is an active process, driven by activated effector T cells. Together, across multiple experiments using B16F10, EL4, LLC, and autochthonous Tg(Grm1)Epv tumors, we observed consistent reconfiguration of the tumor milieu into a proinflammatory phenotype after CTX + VO-OHpic (Fig. 5H) . These changes closely recapitulated the spontaneous changes seen when tumors were grown in genetically defined PTEN Treg -KO mice (cf. Fig. 2) . Similarly, fig. S21 shows that tumors in wild-type mice treated with CTX + VO-OHpic became indistinguishable from tumors grown in PTEN Treg -KO hosts, whereas, conversely, tumors grown in PTEN Treg -KO mice showed no further discernible effect of CTX + VO-OHpic. Thus, although PTEN can be expressed in multiple cell types, its expression in T regs appeared to be an important target of VO-OHpic in tumor-bearing hosts.
Rapid regression of autochthonous tumors
Autochthonous tumors coevolve with the host immune system. This creates profound immune tolerance, and such tumors are much more resistant to the immunologic effects of chemotherapy than transplantable tumors (47) . To test the role of PTEN in a demanding autochthonous setting, we used Tg(Grm1)Epv mice (48), which express the oncogenic Grm1 receptor under the melanocyte-specific Trp2 promoter. These mice progressively develop extensive multifocal melanomas on the ears and tail. When tumors became extensive (4 to 6 months of age), mice were treated with one dose of CTX plus VO-OHpic for 6 days. After treatment, even large, multifocal confluent tumors rapidly regressed (Fig. 6A) . As a measure of regression, we used ear thickness as a proxy, because all ears were extensively involved with tumor (inset graph, Fig.  6A ). Control groups receiving chemotherapy alone, VO-OHpic alone, or no treatment all showed no detectable effect (shown as the pooled controls on the graph). All the effects of CTX + VO-OHpic were lost when mice received depleting monoclonal antibody (mAb) against CD8 (upper inset graph), confirming that the effect was immune-dependent. Histologically, regression was accompanied by a selective elimination of the melanotic tumor cells, leaving underlying tissue intact (Fig. 6B) . FACS analysis of regressing tumors showed emergence of the characteristic Ly6c + CD11b + -activated myeloid DCs (Fig. 6C) , identical to those in the transplantable tumor models mentioned earlier. Tumorinfiltrating host CD8 + T cells lost their PD-1 + exhausted phenotype and up-regulated granzyme B (Fig. 6D ). All T regs in the tumor lost detectable FoxO3a and PD-1 expression after treatment (Fig. 6E) , and the T regs became unstable and began to express CD40L and IL-2 (Fig. 6F) . Thus, even in mice with extensive, multifocal autochthonous tumors, a single dose of chemotherapy caused rapid and widespread tumor regression when PTEN was inhibited.
DISCUSSION
Here, we identify PTEN signaling in T regs as an important, centrally positioned driver of the immunosuppressive milieu in tumors. When this pathway was active, T regs in tumors were highly suppressive; the antigen-presenting cell (APC) population was dominated by PD-L1-expressing DCs, with little evidence of inflammation or cross-presentation, and CD8 + T cells appeared unactivated and exhausted in the tumor. In contrast, if the PTEN pathway was ablated in T regs , then the same tumors became spontaneously inflammatory and immunogenic: T regs in the tumor (but not elsewhere) lost their suppressive phenotype and converted into proinflammatory helper cells (ex-T regs ); the major DC population was changed into a characteristic population of activated myeloid DCs expressing Ly6c, CD11b, and CD103 and producing IL-6; costimulation (CD86) went up and co-inhibition (PD-L1) went down; and CD8 + T cells became activated in the tumor. Thus, the PTEN pathway in T regs dominantly regulated a suite of critical downstream pathways.
Tumors rely on multiple immunosuppressive mechanisms; thus, PTEN-T regs are a part of a larger network, but it was striking that a single pathway in a single cell type was so crucial for the overall immunologic milieu of the tumor. PTEN-T regs were found in three different transplantable tumors and in each of the spontaneous tumors tested in an autochthonous tumor model. It is not yet known how these different tumors all converged on the same suppressive pathway, but insight may come from our finding that PTEN Treg -KO mice were unable to suppress immune responses to apoptotic cells. Tumors are aberrant and have a high rate of constitutive cell turnover-in many respects, they resemble chronic wounds (49) . This chronic, ongoing cell death can become massively increased after chemotherapy or immunotherapy. Thus, the ability to enforce immune suppression in response to apoptotic cells may be an important immune-evasion pathway for tumors, particularly under the stress of chemotherapy or vaccination.
PTEN had connections to the IDO pathway. IDO-activated T regs became dependent on PD-1→PTEN signaling to maintain their suppression, whereas apoptotic tumor cells actively induced PTEN-T regs in an IDO-dependent fashion. However, the tumor-resistant phenotype of PTEN Treg -KO mice was much more robust than that of IDO1-KO mice, and blocking PTEN had a more acute antitumor effect than blocking IDO alone. PTEN is downstream of other important T regactivating signals as well, such as neuropilin-1 (29) . Thus, PTEN appears to be an important nexus for multiple upstream signals in T reg biology. This makes it an attractive target for therapy.
Pharmacologic inhibition of PTEN was synergistic with chemotherapy. In the case of the melanoma models [B16F10 and Tg(Grm1) Epv], this synergy was dramatic. Different tumor types displayed different degrees of regression after CTX + VO-OHpic, and some tumors may recruit more myeloid-derived suppressor cells or other mechanisms that are not as dependent on PTEN. Part of the susceptibility of various tumors may be dictated by the strength of the spontaneous, preexisting CD8 + T cell response against the tumor. Using depletion studies, we found that endogenous host CD8 + T cells were strictly required for the antitumor effect of chemotherapy + PTEN inhibitor. In addition to being cytotoxic effector cells, these CD8 + cells appeared to play an important role as drivers of inflammation. Without the endogenous CD8 + cells, intratumoral T regs never lost their suppressive phenotype, and there was no downstream activation of inflammatory myeloid DCs. Thus, although blocking PTEN rendered the T regs unstable in the face of inflammation, the CD8 + T cells were required to actually trigger that inflammation itself and thus drive reprogramming.
This role for inflammation and T cells differs from the older concept that the immune system might contribute some of the intrinsic efficacy of standard chemotherapy (that is, chemotherapy used by itself) (50). Our model does not speak to this, because we deliberately chose a chemotherapy regimen that had no efficacy by itself against the tumor. It was only when the PTEN inhibitor was added, and new immunologic mechanisms were now unleashed, that the combined chemoimmunotherapy regimen showed efficacy. It was this new, synergistic effect of the combination that was strictly immunedependent.
PTEN-T regs were indispensable for regulating the immune response to apoptotic cells. In mice without tumors, simply injecting apoptotic tumor cells caused rapid local activation of PTEN-T regs , and T cell responses to cell-associated antigens were suppressed. However, if PTEN was blocked or ablated, then the same apoptotic tumor cells were now treated as proinflammatory and caused activation of DCs and crosspresentation of antigen to T cells. Thus, whether the host treated apoptotic cells as immunogenic or tolerogenic was not intrinsic to the dying cells themselves, but rather was a choice enforced by the activated PTEN-T regs . Consistent with this, when PTEN Treg -KO mice were challenged with repetitive injections of apoptotic thymocytes, they rapidly developed multiple lupus-like autoantibodies. This phenotype is very similar to IDO1-deficient mice, challenged with the same regimen of apoptotic cells (23) , which is consistent with our finding that apoptotic cells induced PTEN-T regs via IDO. Thus, we hypothesize that one normal role of the PTEN-T reg pathway is to maintain self-tolerance to apoptotic cells, and this natural tolerogenic pathway is pathologically co-opted by tumors.
Other strains of mice lacking PTEN in T regs spontaneously develop lupus autoantibodies as they age (20, 21) . Our mice, using a different Cre system and different PTEN-floxed mice, had a somewhat milder phenotype and did not develop autoantibodies until late in life. However, both strains developed the same lupus-like autoimmunity, with its characteristic autoantibody response against antigens derived from apoptotic cells. The fact that our strain had late onset of disease was crucial, because it allowed us to demonstrate the markedly and fundamentally altered underlying response to tumors, even in healthy, asymptomatic young mice.
The role of PTEN in self-tolerance introduces the possibility of autoimmune side effects when PTEN inhibitors are used therapeutically. Autoimmunity is always a potential "on-target" toxicity for strategies that aim to break tolerance to tumor cells (51) . However, the PTEN pathway has several attributes that make it attractive for clinical therapy. First, the required duration of inhibitor treatment is brief, being focused just on the specific period when tumor cells are undergoing cell death after chemotherapy or vaccination. Second, the tumor appears to be heavily dependent on the PTEN-T reg pathway for immunosuppression, much more so than normal tissues. This was shown by the spontaneous inflammation seen within the tumor in young, healthy PTEN Treg -KO mice but not seen anywhere else outside the tumor. Third, tumors are mutated and hence potentially more immunogenic than normal tissues (52) . This may contribute to the "driver" CD8 response needed to initiate inflammation within the tumor.
Together, these factors may allow brief, focused dosing with the PTEN inhibitor to achieve selective effects on the tumor while minimizing autoimmune toxicity. The use of intermittent dosing also mitigates the hypothetical concern that PTEN inhibitors might be oncogenic. PTEN is a tumor-suppressor gene, but it is not a transforming oncogene; thus, to have an oncogenic effect, it must be inhibited for a prolonged period and also combined with additional driver oncogenes. Hence, transient intermittent interruption and restoration of PTEN should not be an oncogenic regimen and may actually cause senescence in tumor cells (53) . Together, our findings identify the PTEN pathway in T regs as an important driver of the immunosuppressive tumor microenvironment and a potentially attractive target for therapy.
MATERIALS AND METHODS
Reagents Indoximod (1-methyl-D-tryptophan) and NLG919 were supplied as clinical-grade material by NewLink Genetics Inc. For in vitro studies, indoximod was dissolved in alkaline pH as previously described (34) and diluted in phosphate-buffered saline (PBS) at a final pH of 7.4. Rapamycin (Sigma #R8781) was used at 85 nM. PP242 (Seleckchem #S2218) was used at 100 nM. Human gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] (KVPRNQDWL) and SIINFEKL peptides were synthesized by Southern Biotechnology from the published sequence (54, 55) . VO-OHpic (BioVision #1801-5) was used at 1 mM in vitro unless otherwise specified (37) and at 10 mg kg T reg /DC cocultures Initial activation cocultures. Our T reg coculture system has been previously described (22, 24) . Cocultures were performed in V-bottom wells (Nunc 249952 V96) to ensure cell-cell contact. Rapid isolation of T regs was important; hence, LNs and spleen were mechanically disaggregated by passing once through a 40-mm mesh and then briefly stained on ice and FACS-sorted into ice-cold medium using low-shear fluidics and a large nozzle. IDO + DCs (5 × 10 3 per well) were enriched from TDLNs of B16F10 tumors (days 7 to 11) by sorting for CD11c ) to maintain T reg viability, as previously described (24) . Cultures received either indoximod (200 mM) or NLG919 (1 mM) to inhibit IDO. For aCD3-induced activation, cocultures received aCD3 mAb (0.1 mg/ml; clone 145-2C11, azide-free); in addition, these cultures also always received an IDO inhibitor to ensure that IDO was not active or inducible during coculture.
T reg re-sorting and readout assays. After 2 to 3 days (the time was not critical), activation cocultures were harvested, cells were stained for CD4, and the activated T regs were re-sorted as CD4 Ex vivo T reg assays from vaccine-draining LNs. To measure spontaneous T reg activity in vaccine-draining LNs (VDLNs), we implanted B16F10 tumors in Foxp3-GFP reporter mice. On day 11, mice received hgp100 vaccine in CpG/IFA (incomplete Freund's adjuvant) in the contralateral footpad, with intravenous pmel-1 adoptive transfer. Three days later, the VDLNs were harvested and CD4 + GFP + T regs were sorted and added to readout assays as described in the preceding section.
Antibodies and FACS staining
LNs were prepared by rapidly passing through a 40-mm mesh and then stained using short incubation times (10 min on ice), as previously described (22) . Tumors were disaggregated by treating for 1 hour with collagenase (1 mg/ml; C5138, Sigma), deoxyribonuclease (0.1 mg/ml; D5025, Sigma), and hyaluronidase (0.1 mg/ml; H3884, Sigma) in RPMI 1640 medium.
Conjugated mAbs against the following were from BD Biosciences: CD4 (clone RM4-5), CD8a (clone 53-6. Intracellular antigens were detected using a fixation-permeabilization reagent and a matching perm-wash buffer from eBioscience (catalog #00-5521), with blocking using 5% normal donkey serum, and then acquired immediately after staining. IL-2, IFN-g, and IL-6 were measured after 4 hours of activation with PMA/ionomycin in the presence of brefeldin A as previously described (22) . Unconjugated anti-FoxO3a (4 mg/ml; rabbit mAb, clone 75D8, Cell Signaling Technology) was used in the perm-wash buffer and was detected with donkey anti-rabbit PE (Jackson ImmunoResearch #711-116-152) at 1:100 dilution. All washes were performed in the perm-wash buffer in the cold. Goat anti-Eos (sc-132308) (2 mg/ml) from Santa Cruz Biotechnology was used, followed by cross-adsorbed secondary donkey antigoat APC (705-136-147) from Jackson ImmunoResearch as previously described (22) .
For phospho-specific staining, antibodies were from Cell Signaling Technology, either Alexa Fluor 647-conjugated pAkt-Thr 308 (catalog #3375), pAkt-Ser 473 (catalog #4075), or anti-pS6 (catalog #4851). Cells were washed in PBS, fixed with 2% paraformaldehyde for 10 min at 37°C, prechilled for 1 min, and then permeabilized by slow addition of ice-cold methanol to a final concentration of 90%. Cells were then incubated on ice for 30 min, washed with 1% fetal calf serum/PBS, blocked with the same solution for 10 min at room temperature and then for 1 hour at room temperature, and washed. Cells were acquired immediately after staining.
Mouse strains
All animal studies were approved by the Institutional Animal Care and Use Committee of Georgia Health Sciences University. FoxO3-deficient mice (FoxO3Kca strain) have been previously described (28) IDO-deficient mice (B6 background) have been previously described (59, 60) . PD-1-deficient mice have been previously described (26) .
T regs were identified using GFP reporter mice. To ensure that results were not influenced by a particular reporter strain, we confirmed them using multiple reporter systems. Foxp3 GFP mice (61, 62) , bearing a Foxp3-GFP fusion protein in the coding region of the Foxp3 locus, were the gift of A. Rudensky. Foxp3 DTR mice, with a DTR-GFP fusion construct knocked in to the 3′ untranslated region of the Foxp3 gene (but with a normal Foxp3 coding sequence), were the gift of A. Rudensky (63) . Mice with a BAC-transgenic GFP-Cre fusion protein under the Foxp3 promoter (Foxp3 GFP-Cre ) (36, 64) were obtained from the Jackson Laboratory [NOD/ShiLt-Tg(Foxp3-EGFP/cre)1Jbs/J] and backcrossed in our colony onto the B6 background. These were used for intercrosses with floxed alleles to create T reg -specific deletions, as follows. 
Tumor studies
The Tg(Grm1)Epv mouse strain (48) was the gift of S. Chen (Rutgers University). The B16F10, EL4, E.G7, and LLC cell lines were from the American Type Culture Collection. B16-OVA (B16F10 transfected with full-length chicken OVA) clone MO4 (67) was the gift of A. Houghton (Memorial Sloan Kettering). Tumor implantation was performed as previously described (24), using 1 × 10 5 cells for B16F10 and 1 × 10 6 cells for other cell lines (large inocula were used to ensure rapid tumor engraftment and immune suppression). Tumor volume was calculated from orthogonal diameters using the formula V = L × W 2 × p/6. Indoximod (2 mg/ml) was administered in drinking water as previously described (24) , and NLG919 (6 mg/ml) was similarly administered. VO-OHpic was given at 10 mg kg −1 day −1 ip in 10% DMSO. CAL-101 was given at 30 mg kg −1 day −1 ip in 10% DMSO. For in vivo CD8 depletion studies, mice received anti-CD8 antibody clone YTS 169.4 (BioXcell) given at 200 mg ip 1 day before CTX and then at 100 mg ip every other day throughout the experiment. Indoximod (2 mg/ml; D-1MT) was administered in drinking water as previously described (24) . Mice received approved euthanasia when tumors reached a size of 300 mm 2 (product of orthogonal diameters); death was not used as a planned end point in any study.
Vaccines and T cell adoptive transfers
CpG-1826 (phosphorothioate oligo 5′-TCCATGACGTTCCTGAGCTT-3′) was synthesized from the published sequence (68) by TriLink Biotechnologies. Whole OVA protein was from Sigma (#A-5503). Human gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] was synthesized from the published sequence (54). Vaccines were prepared with 100 mg of OVA protein or 25 mg of peptide, with 50 mg of CpG-1826 in IFA (Sigma F-5506) and administered in the hindlimb footpad. Popliteal LNs were harvested 4 days later. For all adoptive transfers, OT-I or pmel-1 spleen cells were enriched by negative selection using magnetic beads (mouse CD8 isolation kit II, #130-095-236, Miltenyi Biotec). Staining for bead isolation was performed on ice, with short incubation times. Mice received 2 × 10 6 enriched CD8 + cells via the tail vein.
Statistics
Multiple treatment groups were compared by ANOVA with Tukey's honestly significant difference correction. Independent replicates for each experiment in the manuscript are indicated in the figure legends. Error bars always show SD.
SUPPLEMENTARY MATERIALS
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